Names and pronunciation
(a-bal-oh-PAR-a-tide) Tymlos
PDF page 15
Loading InternPractice…
Drug reference
(a-bal-oh-PAR-a-tide) Tymlos
PDF page 15
Func. class.: Parathyroid hormone analog and modifier
PDF page 15
ACTION: A synthetic peptide analog of a parathyroid hormone–related pro- tein, which acts as an agonist at the PTH receptors
PDF page 15
USES: For the treatment of postmeno- pausal women with osteoporosis at high risk for fracture
PDF page 15
CONTRAINDICATIONS: Hypersensitivity Precautions: Breastfeeding, children, pregnancy, radiation, hypercalcemia, hypercalciuria, hyperuricemia, hyper- parathyroidism, renal disease, ortho- static hypotension
PDF page 15
Black Box Warning: Osteogenic sar- coma, new primary malignancy Black Box Warning: Osteosarcoma: increased risk; use product for <2 yr • Pregnancy/breastfeeding: not indicated for women of reproductive potential
PDF page 15
SIDE EFFECTS CNS: Dizziness META: Hypercalcemia, hyperuricemia INTEG: Injection site reactions CV: Orthostatic hypotension
PDF page 15
INTERACTIONS None known NURSING CONSIDERATIONS
PDF page 15
DOSAGE AND ROUTES Postmenopausal women with osteoporosis at high risk for fracture • Adult postmenopausal female: SUBCUT 80 mcg daily
PDF page 15
Available forms: Solution for injection 80 mcg/dose
PDF page 15
Administer: SUBCUT route • Visually inspect for particulate matter and discoloration prior to use • Do not use IV/IM • Needles are not included with the pen; a separate prescription for needles is needed. Use 8-mm, 31-gauge Clickfine needles such as ReliOn, Smart Sense, or TopCare brands • Prime prior to first use to remove air bubbles • Do not inject into areas where skin is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch marks • Rotate site daily and give at the same time A • The first several doses should be given with the patient lying down in case of orthostatic hypotension • Storage: Prior to first use, store pen in refrigerator (do not freeze). After first use, store for up to 30 days at room temperature (68°F-77°F or 20°C-25°C); do not freeze or expose to heat. Keep cap on when not in use. Do not store with a needle attached. Use pen only for 30 days. Dispose of properly
PDF page 15
Assess: • Osteoporosis: prior to and during treatment • Blood studies: serum calcium, uric acid baseline and periodically • Urolithiasis: product may increase the risk of urolithiasis in those with recent or current urolithiasis
PDF page 15
Evaluate: • Therapeutic response: increased bone mineral density
PDF page 15
Patient and caregiver information: • Not to try to inject until patient or caregiver receives training • To receive the first several injections near a place to sit or lie down, until the effect of the injection is known; blood pressure may drop • To inject 1 time each day into lower stomach area (abdomen) just under the skin (SUBCUT); to avoid giving the injec- tion within the 2-inch area around the navel; to rotate injection sites daily • That periodic lab tests will be done • To take at same time each day; that if the dose is forgotten or cannot be taken at the usual time, to take drug as soon as remembered on that day • Not to share pen or pen needles with others even if the needle has been changed • Urolithiasis: to report painful urination
PDF pages 15, 16
PHARMACOKINETICS Protein binding approximately 70%; half- life 0.7 hr
PDF page 15
• Adult postmenopausal female: SUBCUT 80 mcg daily
PDF page 15